 Ethinylestradiol | |
 Drospirenone | |
| Combination of | |
|---|---|
| Ethinylestradiol | Estrogen |
| Drospirenone | Progestogen;Progestin;Antimineralocorticoid;Antiandrogen |
| Clinical data | |
| Trade names | With 30 μg ethinylestradiol: Yasmin, others With 20 μg ethinylestradiol: Yaz, Yasminelle, others |
| Other names | EE/DRSP; drospirenone/estradiol; drospirenone/ethinyl estradiol |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a601050 |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Ethinylestradiol/drospirenone (EE/DRSP), sold under the brand nameYasmin among others, is acombination ofethinylestradiol (EE), anestrogen, anddrospirenone (DRSP), aprogestin,antimineralocorticoid, andantiandrogen, which is used as abirth control pill to preventpregnancy in women.[6][7][4][5][8] It is also indicated for the treatment of moderateacne,premenstrual syndrome (PMS),premenstrual dysphoric disorder (PMDD), anddysmenorrhea (painful menstruation) in women.[7] The medication is takenby mouth and contains 30 μg EE and 3 mg DRSP pertablet (brand names Yasmin, others) or 20 μg EE and 3 mg DRSP per tablet (brand names Yaz, Yasminelle, Nikki, others).[4][5] A formulation withlevomefolic acid (vitamin B9) has also been marketed (brand names Beyaz, Safyral, others), with similar indications.[9][10] EE/DRSP is marketed widely throughout the world.[11]
In 2023, it was the 154th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[12][13]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
